TNFA - TNF Pharmaceuticals, Inc.

0.2631
-0.102   -38.807%

Share volume: 3,289,204
Last Updated: 04-08-2025
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: -0.05%

PREVIOUS CLOSE
CHG
CHG%
$0.37
-0.10
-0.28%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
6%
Profitability 0%
Dept financing 13%
Liquidity 6%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-9.63%
1 Month
2.56%
3 Months
-71.47%
6 Months
-75.65%
1 Year
-79.93%
2 Year
-79.93%
Key data
Stock price
$0.26
P/E Ratio 
0.00
DAY RANGE
$0.25 - $0.33
EPS 
-$9.68
52 WEEK RANGE
$0.32 - $2.16
52 WEEK CHANGE
-$79.93
MARKET CAP 
3.912 M
YIELD 
N/A
SHARES OUTSTANDING 
2.370 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.66
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,907,736
AVERAGE 30 VOLUME 
$1,255,490
Company detail
CEO: Mitchell Glass
Region: US
Website: tnfpharma.com
Employees: 6
IPO year: 2008
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Recent news
loading